Vivos Therapeutics Inc. (VVOS) shares plunged 26.1% on Thursday after the company announced a $4.3 million registered offering of 1.36 million shares. The offering, expected to close on September 20, will generate approximately $4.3 million in gross proceeds and will be used for working capital and general corporate purposes. This news follows a recent discussion on whether VVOS is a good stock to buy, with analysts focusing on the company’s capital allocation strategy, including dividend payouts and stock buyback programs.
Results for: Direct Offering
Eastside Distilling, a craft spirits producer, announced the completion of a registered direct offering, raising $442,042 from a single institutional investor at a premium price. The funds will be used to support the company’s growth and expansion plans.
Ensysce Biosciences (ENSC) shares plummeted 30% on Thursday after the company announced a $5 million registered direct offering and concurrent private placement. The move involved issuing shares at a discounted price, raising concerns among investors. The company plans to use the funds to advance its drug development programs.
Virax Biolabs Group Limited (VRAX) shares are down today following the announcement of a $5 million registered direct offering. The company plans to use the proceeds for working capital and general corporate purposes. While the stock has seen significant gains recently, its high RSI suggests it might be overbought.